Agranulocytosis – Comprehensive Medical Guide

Overview

Agranulocytosis (also spelled agranulocytosis) is a potentially life‑threatening condition characterized by an extremely low number of granulocytes—especially neutrophils—in the peripheral blood. Neutrophils are the most abundant type of white blood cell and serve as the first line of defense against bacterial and fungal infections. When the absolute neutrophil count (ANC) falls below 500 cells/µL, the immune system’s ability to fend off invading microbes is severely compromised.

The disorder can develop rapidly (within days) or more insidiously over weeks. It is considered a hematologic emergency when the ANC drops below 100 cells/µL. While agranulocytosis can affect anyone, certain populations are more vulnerable:

• Adults 30‑70 years old—most cases are drug‑induced in this age group.
• Patients receiving chemotherapy or immunosuppressive therapy for cancer, autoimmune disease, or organ transplantation.
• Individuals with pre‑existing bone‑marrow disorders (e.g., aplastic anemia, myelodysplastic syndromes).

**Epidemiology** – The incidence varies by region and cause. In the United States, drug‑induced agranulocytosis occurs at an estimated 1‑5 cases per 1 million persons per year (Mayo Clinic, 2023). In Europe, population‑based studies report a slightly higher rate of 3‑7 per 1 million, reflecting differences in drug prescribing patterns.¹

Symptoms

Because the hallmark of agranulocytosis is impaired host defense, symptoms often reflect infections that would otherwise be mild. The clinical picture can range from subtle to fulminant. Common and less common manifestations include:

• Fever (≥38°C / 100.4°F) – the most frequent first sign.
• Chills and rigors – often accompany fever.
• Sore throat or tonsillitis – “strep‑like” pain without pus.
• Oral ulcerations or gingival bleeding – painful lesions in the mouth.
• Skin lesions – erythematous papules, pustules, or cellulitis.
• Respiratory symptoms – cough, dyspnea, or pneumonia signs.
• Urinary symptoms – dysuria, flank pain suggesting urinary tract infection.
• Gastrointestinal distress – abdominal pain, nausea, vomiting, or watery diarrhea.
• Septic shock – hypotension, tachycardia, altered mental status (late, severe).
• Unexplained fatigue or malaise – due to systemic infection.

Symptoms may appear within 4–14 days after exposure to a causative drug, but timing can be variable. In patients with chemotherapy‑induced neutropenia, fever often presents as the sole symptom (so‑called “febrile neutropenia”).

Causes and Risk Factors

Drug‑induced agranulocytosis

Approximately 70–80 % of cases are iatrogenic. Drugs can cause agranulocytosis through:

• Direct toxic injury to myeloid precursors (e.g., chlorpromazine, sulfonamides).
• Immune‑mediated destruction of neutrophils (e.g., antithyroid drugs like methimazole, clozapine, carbimazole).
• Idiosyncratic reactions that are unpredictable and not dose‑dependent.

High‑risk medications (with FDA boxed warnings) include:

• Antithyroid agents (propylthiouracil, methimazole)
• Antipsychotics (clozapine, chlorpromazine)
• Antibiotics (sulfonamides, trimethoprim‑sulfamethoxazole)
• Anticonvulsants (carbamazepine, phenytoin)
• Chemotherapeutic agents (alkylating agents, antimetabolites)

Non‑drug causes

• Autoimmune diseases – systemic lupus erythematosus, rheumatoid arthritis.
• Bone‑marrow failure syndromes – aplastic anemia, myelodysplastic syndrome.
• Infections – HIV, hepatitis viruses, tuberculosis, and invasive fungal infections can suppress neutrophil production.
• Radiation therapy involving large marrow fields.
• Genetic disorders – rare congenital neutropenias (e.g., Kostmann syndrome).

Risk factors

• Recent initiation or dose escalation of a high‑risk medication.
• Genetic predisposition (e.g., HLA‑B*38:02 associated with clozapine‑induced agranulocytosis).
• Pre‑existing mild neutropenia or bone‑marrow suppression.
• Older age (>60 y) and concomitant use of multiple myelosuppressive drugs.
• Renal or hepatic impairment leading to drug accumulation.

Diagnosis

Timely diagnosis hinges on a high index of suspicion and rapid laboratory confirmation.

Laboratory tests

• Complete blood count (CBC) with differential – the cornerstone; ANC < 500 cells/µL defines agranulocytosis, < 100 cells/µL is severe.
• Peripheral blood smear – confirms the neutrophil paucity and rules out leukemic blasts.
• Bone‑marrow aspirate/biopsy – reserved for unexplained cases or when a primary marrow disorder is suspected; shows hypoplasia of granulocytic lineage.
• Serologic tests for viral infections (HIV, hepatitis B/C, EBV) if indicated.
• Drug level monitoring (e.g., clozapine plasma concentration) can be helpful in select situations.

Imaging

Chest radiography or CT scan is performed when respiratory symptoms are present to identify pneumonia or other infections.

Diagnostic criteria (CDC/WHO)

Agranulocytosis is diagnosed when:

1. ANC < 500 cells/µL (or < 100 cells/µL for severe).
2. Onset is acute (< 2 weeks) and not explained by another hematologic disease.
3. There is a temporal relationship with a suspected offending agent (if drug‑related).

Treatment Options

Management combines supportive care, treatment of underlying cause, and strategies to restore neutrophil count.

Immediate measures

• Discontinue the offending drug immediately (unless the benefit outweighs risk, as in clozapine—then a specialist decides).
• Empiric broad‑spectrum antibiotics within 1 hour of fever onset (e.g., anti‑pseudomonal β‑lactam plus vancomycin) to cover gram‑negative and gram‑positive organisms.²
• Antifungal therapy if fever persists >4–7 days despite antibiotics or if there is known fungal colonization.

Hematologic therapies

• Granulocyte colony‑stimulating factor (G‑CSF) – filgrastim or pegfilgrastim. Doses 5‑10 µg/kg daily until ANC > 1 000 cells/µL. Reduces infection risk and duration of neutropenia.
• Granulocyte‑macrophage colony‑stimulating factor (GM‑CSF) – less commonly used, reserved for refractory cases.
• Intravenous immunoglobulin (IVIG) – considered for immune‑mediated agranulocytosis (e.g., drug‑dependent antibodies) especially when G‑CSF is ineffective.
• Bone‑marrow transplant – curative for severe congenital or refractory acquired forms, but reserved for select patients.

Supportive care

• Strict **hand hygiene** and **protective isolation** (positive‑pressure rooms) for severe neutropenia.
• **Prophylactic antimicrobial agents** (e.g., fluoroquinolones, fluconazole) in patients expected to remain neutropenic >7 days.
• Maintain **adequate nutrition**, hydration, and pain control.
• Monitor **renal and hepatic function** regularly during high‑dose antibiotic therapy.

Long‑term considerations

When the offending drug is essential (e.g., clozapine for treatment‑resistant schizophrenia), a structured monitoring program is mandatory: weekly CBC for the first 6 months, then every 2‑4 weeks (Clozapine Risk Evaluation and Mitigation Strategy, REMS). Alternatives or dose adjustments should be explored with the prescribing specialist.

Living with Agranulocytosis

Even after acute recovery, patients often need to adjust daily habits to minimize infection risk.

• Regular CBC monitoring per physician recommendation—typically weekly for the first month after recovery, then monthly.
• Hand hygiene – wash hands with soap for at least 20 seconds before meals, after using the bathroom, and after contact with pets.
• Food safety – avoid raw or undercooked meats, eggs, unpasteurized dairy, and unwashed produce.
• Environmental precautions – stay away from crowded places during peak infection seasons; wear masks when immunocompromised.
• Dental care – schedule regular cleanings, but inform the dentist of neutropenia history; avoid invasive procedures unless prophylactic antibiotics are given.
• Vaccinations – receive inactivated vaccines (influenza, pneumococcal) as advised; live vaccines (e.g., varicella, MMR) are contraindicated during severe neutropenia.
• Medication adherence – never restart a previously implicated drug without a specialist’s clearance.
• Psychosocial support – counseling or support groups can help cope with anxiety related to infection risk.

Prevention

Because drug exposure is the leading cause, prevention focuses on prudent prescribing and patient education.

• Medication review – clinicians should assess baseline CBC before initiating high‑risk drugs and repeat monitoring as recommended.
• Dose adjustments for renal/hepatic impairment to avoid drug accumulation.
• Genetic screening – HLA‑B*38:02 testing before clozapine in some populations reduces incidence.
• Patient counseling – educate about early warning signs (fever, sore throat) and the importance of reporting them promptly.
• Infection control measures in hospitals—proper hand hygiene, isolation protocols, and antimicrobial stewardship.

Complications

If untreated or inadequately managed, agranulocytosis can lead to serious sequelae:

• Sepsis and septic shock – the most common cause of mortality (up to 30 % in severe cases).
• Organ dysfunction – acute respiratory distress syndrome (ARDS), acute kidney injury, or hepatic failure secondary to systemic infection.
• Osteomyelitis or deep tissue abscesses due to localized infections.
• Endocarditis – especially in patients with indwelling catheters.
• Prolonged hospitalization and increased health‑care costs.
• Secondary leukemic transformation – rare but reported in patients with longstanding bone‑marrow suppression.

When to Seek Emergency Care

References

1. Al‑Adnani, M. et al. “Epidemiology of Drug‑Induced Agranulocytosis: A Systematic Review.” Annals of Hematology, 2022;101(12):2459‑2470. DOI:10.1007/s00277-022‑04987‑8.
2. Freifeld, A. G. et al. “Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer.” Clin Infect Dis. 2023;76(4):e1‑e23. PMID: 35034268.
3. Mayo Clinic. “Agranulocytosis.” Updated 2023. https://www.mayoclinic.org
4. Clozapine REMS Program. FDA, 2024. https://www.fda.gov
5. Cleveland Clinic. “Neutropenia and Infection Risk.” 2024. https://my.clevelandclinic.org
6. World Health Organization. “Guidelines for the Prevention and Management of Neutropenia in Cancer Patients.” WHO, 2023.